Showing results (151-160 of 841) with videos related to

Sort By:
Pageof 85
Cortex; a Journal Devoted to the Study of the Nervous System and Behavior|July 28, 2018
Beta oscillatory power modulation reflects the predictability of pitch changeAndrew Chang, Dan J Bosnyak, Laurel J Trainor
Ophthalmic Surgery, Lasers & Imaging Retina|March 26, 2024
Case Report: Macula Structural and Functional Assessment in Nab-Paclitaxel-Related Cystoid Macular EdemaLawrence Kwok, Alina Mahmood, Sanjeev Kumar, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|December 27, 2019
Ultra-Widefield Fluorescein Angiography as a Biomarker for Response to Switch in Therapy in Persistent DMEBobak Bahrami, Thomas Hong, Tunde Peto, et al.
American Journal of Respiratory and Critical Care Medicine|June 10, 2026
Mepolizumab Efficacy in COPD: Insights from Longitudinal Patterns of Blood Eosinophil Counts and Their Variability Across Three Clinical TrialsGerard J Criner, Henrik Watz, MeiLan K Han, et al.
The European Respiratory Journal|August 26, 2022
Utility of whole genome sequencing in assessing risk and clinically relevant outcomes for pulmonary fibrosisDavid Zhang, Chad A Newton, Binhan Wang, et al.
Respiratory Research|July 11, 2020
Composite endpoints in COPD: clinically important deterioration in the UPLIFT trialKlaus F Rabe, David M G Halpin, MeiLan K Han, et al.
American Journal of Respiratory and Critical Care Medicine|April 20, 2018
Patient-reported Outcomes for the Detection, Quantification, and Evaluation of Chronic Obstructive Pulmonary Disease ExacerbationsAlex J Mackay, Konstantinos Kostikas, Lindsey Murray, et al.
ERJ Open Research|December 17, 2025
Short-acting β2-agonist use, exacerbation risk and triple therapy in COPD: post hoc analyses of ETHOSJohn R Hurst, Dave Singh, Fernando J Martinez, et al.
Therapeutic Advances in Respiratory Disease|July 11, 2022
Predictive modeling of COPD exacerbation rates using baseline risk factorsDave Singh, John R Hurst, Fernando J Martinez, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 31, 2016
Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study designStephen I Rennard, Fernando J Martinez, Klaus F Rabe, et al.
Pageof 85